Towards a new combination therapy for tuberculosis with next generation benzothiazinones

EMBO Molecular Medicine

Volumn 6, Issue 3, 2014, Pages 372-383

  Makarov, Vadim ^a,b   Lechartier, Benoit ^a,c   Zhang, Ming ^a,c   Neres, João ^a,c   van der Sar, Astrid M ^d   Raadsen, Susanne A ^d,h   Hartkoorn, Ruben C ^a,c   Ryabova, Olga B ^a,b   Vocat, Anthony ^a,c   Decosterd, Laurent A ^e   Widmer, Nicolas ^e   Buclin, Thierry ^e   Bitter, Wilbert ^d,f   Andries, Koen ^g   Pojer, Florence ^a,c   Dyson, Paul J ^c   Cole, Stewart T ^a,c  

^a More Medicines for Tuberculosis ^*  (United Kingdom)

^b BACH INSTITUTE OF BIOCHEMISTRY   (Russian Federation)

^c EPFL   (Switzerland)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f VU UNIVERSITY AMSTERDAM   (Netherlands)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

^h Janssen Infectious Diseases ^*  (Netherlands)

Author keywords

Benzothiazinones; Combination regimens; DprE1; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AROMATIC NITRO COMPOUND; BEDAQUILINE; BENZOTHIAZINE DERIVATIVE; BTZ 043; CYSTEINE; DECAPRENYLPHOSPHORYL BETA DEXTRO RIBOFURANOSE 2' EPIMERASE; EPIMERASE; ISONIAZID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PBTZ 169; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CORYNEBACTERIUM DIPHTHERIAE; CORYNEBACTERIUM GLUTAMICUM; COVALENT BOND; CRYSTAL STRUCTURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG UPTAKE; EMBRYO; ENZYME INHIBITION; FEMALE; FISH MODEL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE MODEL; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM MARINUM; MYCOBACTERIUM MASSILIENSE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REDUCTION; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; ZEBRA FISH;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; EMBRYO, NONMAMMALIAN; HEP G2 CELLS; HUMANS; LUNG; MICE; MOLECULAR DYNAMICS SIMULATION; MYCOBACTERIUM TUBERCULOSIS; PIPERAZINES; SPIRO COMPOUNDS; SPLEEN; THIAZINES; TUBERCULOSIS; ZEBRAFISH;

EID: 84896716778     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201303575     Document Type: Article

References (29)

1. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L (2011) Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145: 39-53
2. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227
3. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, Futterer K, Besra GS (2012) Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci U S A 109: 11354-11359
4. Davis JM, Clay H, Lewis JL, Ghori N, Herbomel P, Ramakrishnan L (2002) Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17: 693-702
5. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P et al (2012) 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380: 986-993
6. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G et al (2009) The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405
7. Gler MT (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160
8. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K (2011) The challenge of new drug discovery for tuberculosis. Nature 469: 483-490
9. Lechartier B, Hartkoorn RC, Cole ST (2012) In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 5790-5793
10. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE (2003) Combinatorial lead optimization of [1, 2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 5: 172-187
11. Makarov V (2011) Process for the preparation of 2-amino-substituted 1, 3-benzothiazine-4-ones. Vol. WO 2011132070.
12. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP et al (2009) Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324: 801-804
13. Makarov V, Riabova OB, Yuschenko A, Urlyapova N, Daudova A, Zipfel PF, Mollmann U (2006) Synthesis and antileprosy activity of some dialkyldithiocarbamates. J Antimicrob Chemother 57: 1134-1138
14. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro AL, Buroni S, Skovierova H, Dianiskova P, Mikusova K et al (2010) Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Mol Microbiol 77: 1172-1185
15. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466
16. Meijer AH, van der Sar AM, Cunha C, Lamers GE, Laplante MA, Kikuta H, Bitter W, Becker TS, Spaink HP (2008) Identification and real-time imaging of a myc-expressing neutrophil population involved in inflammation and mycobacterial granuloma formation in zebrafish. Dev Comp Immunol 32: 36-49
17. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Rottger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP et al (2012) Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4: 150ra121
18. Pasca MR, Degiacomi G, Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L et al (2010) Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 54: 1616-1618
19. Puttinaowarat S, Thompson KD, Adams A (2000) Mycobacteriosis: detection and identification of aquatic Mycobacterium species. Fish Vet J 5: 6-21
20. Stinear TP, Seemann T, Harrison PF, Jenkin GA, Davies JK, Johnson PD, Abdellah Z, Arrowsmith C, Chillingworth T, Churcher C et al (2008) Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res 18: 729-741
21. Stoop EJ, Schipper T, Huber SK, Nezhinsky AE, Verbeek FJ, Gurcha SS, Besra GS, Vandenbroucke-Grauls CM, Bitter W, van der Sar AM (2011) Zebrafish embryo screen for mycobacterial genes involved in the initiation of granuloma formation reveals a newly identified ESX-1 component. Dis Model Mech 4: 526-536
22. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN et al (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966
23. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE III et al (2012) SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809
24. Tiwari R, Moraski GC, Krchnak V, Miller PA, Colon-Martinez M, Herrero E, Oliver AG, Miller MJ (2013) Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents. J Am Chem Soc 135: 3539-3549
25. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K (2010) Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-beta-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 132: 13663-13665
26. Trefzer C, Skovierova H, Buroni S, Bobovska A, Nenci S, Molteni E, Pojer F, Pasca MR, Makarov V, Cole ST et al (2012) Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-beta-d-ribofuranose 2′-oxidase DprE1. J Am Chem Soc 134: 912-915
27. Vera-Cabrera L, Campos-Rivera MP, Gonzalez-Martinez NA, Ocampo-Candiani J, Cole ST (2012) In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis. Antimicrob Agents Chemother 56: 3984-3985
28. WHO (2012) Global Tuberculosis Report 2012, Geneva: World Health Organization.
29. Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discovery 12: 388-404